A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.
Data released today show that MR-guided focused ultrasound (MRgFUS) is a more effective option for a broader population of uterine fibroid sufferers.
US Bill Clinton announced new agreements that significantly lower the price of AIDS treatment for second-line anti-retroviral drugs (ARVs), drugs required in patients who develop resistance to first-line treatment and which currently cost 10 times the price of first-line therapy.
Keeping a healthy heart beating requires the production of a constant supply of energy, a feat depending on the coordination of several genetic programs. Now, researchers report in the May issue of Cell Metabolism, a publication of Cell Press, that two closely related receptors can act together or separately to pull all of the strings.
The National Cancer Institute has awarded a five-year, $10.7 million grant to Virginia Commonwealth University Massey Cancer Center researchers to develop a new form of radiation therapy that will enable the safe administration of more aggressive cancer treatments.
Two new studies by Dartmouth pediatricians underscore the significant impact that movies have in influencing teens to smoke. The studies show that movies deliver billions of smoking impressions to American teens; and that even teens outside the US are affected by smoking images in films distributed internationally by American studios.
Implanted pumps improved heart function enough in a small percentage of patients awaiting a heart transplant that they were able to leave the hospital without a pump and without a new heart, according to a study in Circulation: Journal of the American Heart Association.
Roche announced that the European Commission has approved the use of Herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer.
Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced that data from a 36-week, randomized, doubleblind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated.
Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), announced that the Company has received two U.S. Food and Drug Administration (FDA) approvals related to its ENJUVIA(TM) (synthetic conjugated estrogens, B) product.